20736-11-2

Usage

Uses

Used in Pharmaceutical Industry:
C-6-G HYDRATE-TRIFLUOROACETATE is used as an excipient for the formulation of various pharmaceutical products. It acts as a solvent, sweetening agent, and humectant, enhancing the stability and bioavailability of active ingredients.
Used in Cosmetics Industry:
C-6-G HYDRATE-TRIFLUOROACETATE is used as a humectant in the formulation of cosmetics and personal care products. It helps to retain moisture, providing a smooth and hydrated feel to the skin.
Used in Food Industry:
C-6-G HYDRATE-TRIFLUOROACETATE is used as a humectant, emulsifier, and sweetener in the food industry. It helps to maintain the texture, taste, and shelf life of various food products.
Used in Oral Health Products:
C-6-G HYDRATE-TRIFLUOROACETATE is used as a humectant and solvent in the formulation of oral health products, such as toothpaste and mouthwashes. It helps to maintain the consistency and effectiveness of these products.
Used in Industrial Applications:
C-6-G HYDRATE-TRIFLUOROACETATE is used as a solvent and humectant in various industrial applications, such as the production of inks, resins, and lubricants. It helps to improve the performance and stability of these products.
Used in Energy Storage:
C-6-G HYDRATE-TRIFLUOROACETATE is used as a component in the production of biodiesel and other biofuels. It serves as a renewable energy source, contributing to the reduction of greenhouse gas emissions and the promotion of sustainable energy solutions.
Used in Research and Development:
C-6-G HYDRATE-TRIFLUOROACETATE is used as a starting material and intermediate in the synthesis of various organic compounds for research and development purposes. Its versatile chemical properties make it a valuable asset in the field of organic chemistry.

InChI:InChI=1/C24H29NO9/c1-25-8-7-24-11-4-6-14(32-23-18(28)16(26)17(27)20(34-23)22(29)30)21(24)33-19-13(31-2)5-3-10(15(19)24)9-12(11)25/h3-6,11-12,14,16-18,20-21,23,26-28H,7-9H2,1-2H3,(H,29,30)/t11-,12+,14-,16-,17-,18+,20-,21-,23+,24-/m0/s1

Upstream product

• 76-57-3 codeine 
• 2616-64-0 UDP-glucuronic acid 
• 6919-98-8 2,3,4-tri-O-acetyl-1-bromo-1-deoxy-β-D-glucopyranuronic acid methy ester 
• 20736-10-1 methyl[codein-6-yl-2,3,4-tri-O-acetyl-β-D-glucopyranosid]uronate 

Relevant academic research and scientific papers

Glucuronidation of paracetamol by human liver microsomes in vitro: Enzyme kinetic parameters and interactions with short-chain aliphatic alcohols and opiates

In this study, glucuronidation of paracetamol (CAS 103-90-2) by human liver microsomes and the effects of aliphatic alcohols and opiates were investigated. Paracetamol glucuronidation was optimised for various incubation conditions. Ten different aliphatic alcohols and the opiates morphine, codeine and dihydrocodeine were analysed as inhibitors of paracetamol glucuronidation. Furthermore, the effects of paracetamol on morphine-3 and codeine glucuronidation were investigated. Enzyme kinetic analysis was carried out via determination of the parameters Km, Vmax, Ki and the type of inhibition. Except for methanol and ethanol, all investigated alcohols inhibited glucuronidation of paracetamol. Ki values ranged between 4.59 mmol/l (n-pentanol) and 340.54 mmol/l (2-propanol). Extent of inhibition strongly depended on the structure and clearly increased with the length of the alkyl chain. All tested opiates inhibited paracetamol glucuronidation with Ki values between 4.02 mmol/l (dihydrocodeine) and 11.44 mmol/l (morphine). Paracetamol itself turned out to be an inhibitor of opiate glucuronidation. The apparent Ki values were 4.62 mmol/l (inhibition of morphine-3 glucuronidation) and 9.44 mmol/l (inhibition of codeine glucuronidation). A mixed inhibition type was determined for all substances. The in vitro studies show a great inhibition potential for the analysed substances. Transferring the results to the in vivo situation, a higher liver toxicity of paracetamol can be assumed, if concomitantly a lot of alcoholic beverages with congener alcohols - e.g. fruit schnapps or whisky - are drunk or if opiates - as analgesics or narcotics - are taken in higher doses. ECV Editio Cantor Verlag.

Process for preparation of 4,5-Epoxymorphinan-6-oxyglucuronides

Conjugation of 4,5-Epoxymorphinan-6-ols with Bromoglucuronides in the presence of Zinc containing compounds as activator under conditions capable of forming 4,5-Epoxymorphinan-6-oxyglucuronides is disclosed. This novel approach provides an efficient metho

Selective synthesis of both isomers of morphine 6-β-D-glucuronide and their analogs

A stereoselective synthesis of both isomers of the pharmaceutically important morphine 6-β-D-glucuronide (M6G) and its analogs was developed. The method is based on the use of ZnBr2 for the key coupling reaction. It was shown that the α/β stere

Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide

Purpose. The antinociceptive and immunosuppressive effects of codeine and codeine 6-glucuronide were determined in rats after intracerebroventricular administration. Methods. Codeine 6-glucuronide was synthesized using a modification of the Koenigs-Knorr reaction. A lipophilic intermediate formed during synthesis, methyl [codein-6-yl-2,3,4-tri-O-acetyl-β-D-glucopyranosid] uronate, was also tested. Morphine was used as a positive control to compare antinociceptive potencies of these compounds. Results. All compounds tested produced significant analgesic responses, as assessed by the tail flick model. Additionally, codeine 6-glucuronide showed significantly less immunosuppressive effects than codeine in vitro. Conclusions. We conclude that codeine 6-glucuronide and related compounds may have clinical benefit in the treatment of pain in immune compromised patients.

A synthesis of morphine-6-glucuronide

A practical synthesis of morphine-6-glucuronide from 3-acetylmorphine and methyl 2α-bromo-3,4,5-tri-O-acetylglucuronate is described. Similar syntheses of codeine-6-glucuronide, codeine-6-glucoside and morphine-6-glucoside are also documented.